Medherant

Executive Summary

Medherant is a UK-based clinical-stage pharmaceutical company focused on transdermal drug delivery via its proprietary TEPI Patch® technology. The platform is a solvent-free, drug-in-adhesive patch designed for controlled, convenient delivery through the skin, addressing limitations of existing transdermal systems. The company's lead candidate is a testosterone patch for Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women, a condition with significant unmet need as current treatments are limited. Medherant has completed preclinical studies and is advancing toward Phase 1 clinical trials. The TEPI Patch technology also has potential for other hormones and central nervous system (CNS) drugs, offering multiple pipeline opportunities. As a private, early-stage company, Medherant's near-term value hinges on successful clinical proof-of-concept and securing partnerships or financing for further development. The HSDD market represents a large opportunity (~$2B+ globally), and an effective, non-invasive testosterone patch could capture significant share. However, the company faces typical clinical and regulatory risks, and no revenue streams are yet established.

Upcoming Catalysts (preview)

• Q4 2027Phase 1 clinical data readout for testosterone patch (HSDD)55% success
• Q2 2027Partnership or licensing deal for TEPI Patch platform40% success
• Q3 2027Announcement of Series B financing round60% success